We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Development of Neurodegenerative Diseases Linked to Astrocyte Nitric Oxide Signaling

By LabMedica International staff writers
Posted on 15 Dec 2015
Nitric oxide (NO) signaling, initiated by brain astrocytes, has been linked to the destruction of neurons that characterizes many neurodegenerative diseases.

Astrocytes are now thought to play a number of active roles in the brain, including the secretion or absorption of neural transmitters and maintenance of the blood–brain barrier.

To study cellular events that occur in the brain during the progress of neurological disorders, investigators at Brigham and Women's Hospital (Boston, MA, USA) developed a fruit fly model of Alexander disease, a rare degenerative neurological disorder caused by astrocyte dysfunction.

Using this model system, the investigators identified astrocyte-derived NO as a signaling molecule triggering astrocyte-mediated neuronal degeneration. More...
NO acted through cGMP signaling in neurons to promote cell death. Astrocytes themselves also degenerated, via the DNA damage response and p53 protein.

Results from the fruit fly model were confirmed in a mouse model. Furthermore, evidence of activation of the NO pathway was detected in samples from human patients with Alexander disease.

"We are excited to be contributing to a growing area of study of how astrocytes contribute to neurodegeneration, and to have uncovered a role for NO as a neuronal cell death signaling molecule," said senior author Dr. Mel B. Feany, a senior pathologist at Brigham and Women's Hospital. "Our findings define a potential mechanism for neuronal cell death in Alexander disease and possibly other neurodegenerative diseases with astrocyte dysfunction."

The study was published in the November 26, 2015, online edition of the journal Nature Communications.

Related Links:

Brigham and Women's Hospital



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Total Laboratory Automation Solution
SATLARS Mini T8
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.